{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T15:31:25Z","timestamp":1789140685835,"version":"build-2803163510"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["canadianjournalofophthalmology.ca","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Ophthalmology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jcjo.2026.02.009","type":"journal-article","created":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T12:19:25Z","timestamp":1773058765000},"page":"982-989","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Faricimab for recalcitrant neovascular age-related macular degeneration: a real-life study following aflibercept nonresponse"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5469-3963","authenticated-orcid":false,"given":"Carolina","family":"Bernal-Morales","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-4493-5772","authenticated-orcid":false,"given":"Sol","family":"Burgos Herrera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lena","family":"Giralt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0800-3719","authenticated-orcid":false,"given":"Socorro","family":"Alforja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5931-4539","authenticated-orcid":false,"given":"Barbara","family":"Romero-N\u00fa\u00f1ez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saray","family":"Catalan-Coronado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Bilbao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Sala-Puigdollers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Pelegrin-Colas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2338-8143","authenticated-orcid":false,"given":"Javier","family":"Zarranz-Ventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo","family":"Adan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1812-9323","authenticated-orcid":false,"given":"Ricardo","family":"Casaroli-Marano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0548-0539","authenticated-orcid":false,"given":"Marc","family":"Figueras-Roca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcjo.2026.02.009_bib0001","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2023.2222545","article-title":"Incidence and prevalence of neovascular age-related macular degeneration: 15-year epidemiological study in a population-based cohort in Finland","volume":"55","author":"Korva-Gurung","year":"2023","journal-title":"Ann Med"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0002","doi-asserted-by":"crossref","DOI":"10.1016\/S2214-109X(13)70145-1","article-title":"Global prevalence of age-related macular degeneration and disease burden projection for 2020 and 2040: A systematic review and meta-analysis","volume":"2","author":"Wong","year":"2014","journal-title":"Lancet Glob Health"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0003","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1007\/s10198-009-0207-9","article-title":"The direct, indirect and intangible costs of visual impairment caused by neovascular age-related macular degeneration","volume":"11","author":"Ke","year":"2010","journal-title":"Eur J Health Econ"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0004","doi-asserted-by":"crossref","first-page":"927","DOI":"10.3390\/ph16070927","article-title":"Visual outcomes of anti-VEGF treatment on neovascular age-related macular degeneration: a real-world population-based cohort study","volume":"16","author":"Korva-Gurung","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0005","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.oret.2024.01.004","article-title":"European unmet needs in the management of neovascular age-related macular degeneration in daily practice: data from the Fight Retinal Blindness! Registry","volume":"8","author":"Boudousq","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0006","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/j.ophtha.2024.02.014","article-title":"TENAYA and LUCERNE: two-year results from the phase 3 neovascular age-related macular degeneration trials of faricimab with treat-and-extend dosing in year 2","volume":"131","author":"Khanani","year":"2024","journal-title":"Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0007","first-page":"3574","article-title":"The real-world efficacy and safety of faricimab in neovascular age-related macular degeneration: the TRUCKEE study\u20146 month results","volume":"37","author":"Khanani","year":"2023","journal-title":"Eye (Basingstoke)"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0008","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1038\/s41433-025-03616-5","article-title":"1-Year real-world outcomes of faricimab in previously treated neovascular age-related macular degeneration","volume":"39","author":"Janmohamed","year":"2025","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0009","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.oret.2024.07.020","article-title":"Real-world 1-year outcomes of treatment-intensive neovascular age-related macular degeneration switched to faricimab","volume":"9","author":"Sim","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0010","doi-asserted-by":"crossref","DOI":"10.3389\/fopht.2023.1346322","article-title":"Initial experiences of switching to faricimab for neovascular age-related macular degeneration and polypoidal choroidal vasculopathy in an Asian population","volume":"3","author":"Ibrahim","year":"2024","journal-title":"Front Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0011","doi-asserted-by":"crossref","DOI":"10.1136\/bmjophth-2024-001967","article-title":"Switching to faricimab from the current anti-VEGF therapy: evidence-based expert recommendations","volume":"10","author":"Wong","year":"2025","journal-title":"BMJ Open Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0012","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1097\/IAE.0000000000004322","article-title":"Real-world long-term outcomes of intravitreal faricimab in previously treated chronic neovascular age-related macular degeneration","volume":"45","author":"Ambati","year":"2025","journal-title":"Retina"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0013","doi-asserted-by":"crossref","first-page":"4029","DOI":"10.2147\/OPTH.S482948","article-title":"Real-world-data of treatment-na\u00efve and previously treated patients receiving up to 3 injections of faricimab in neovascular age-related macular degeneration","volume":"18","author":"Kunzmann","year":"2024","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0014","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s40942-025-00669-2","article-title":"Deep learning assisted analysis of biomarker changes in refractory neovascular AMD after switch to faricimab","volume":"11","author":"Hafner","year":"2025","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0015","doi-asserted-by":"crossref","first-page":"423","DOI":"10.3390\/jcm14020423","article-title":"Clinical outcomes following a switch of therapy to faricimab in patients affected by neovascular age-related macular degeneration","volume":"14","author":"Wolfrum","year":"2025","journal-title":"J Clin Med"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0016","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.2147\/OPTH.S409822","article-title":"Initial real-world experience with faricimab in treatment-resistant neovascular age-related macular degeneration","volume":"17","author":"Leung","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0017","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s10792-024-03297-1","article-title":"Switch to faricimab after initial treatment with aflibercept in eyes with neovascular age-related macular degeneration","volume":"44","author":"Aldhanhani","year":"2024","journal-title":"Int Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0018","doi-asserted-by":"crossref","first-page":"2153","DOI":"10.1007\/s00417-024-06421-0","article-title":"Short-term outcomes of treatment switch to faricimab in patients with aflibercept-resistant neovascular age-related macular degeneration","volume":"262","author":"Schneider","year":"2024","journal-title":"Graefe\u2019s Arch Clin Exper Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0019","doi-asserted-by":"crossref","first-page":"2985","DOI":"10.1007\/s40123-024-01036-4","article-title":"One-year real-world outcomes of intravitreal faricimab for previously treated neovascular age-related macular degeneration","volume":"13","author":"Cancian","year":"2024","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0020","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.oret.2025.03.015","article-title":"One-year outcomes after switching to faricimab in eyes with pretreated neovascular age-related macular degeneration","volume":"9","author":"Grimaldi","year":"2025","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0021","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1007\/s00417-023-06319-3","article-title":"Intravitreal faricimab for neovascular age-related macular degeneration previously treated with traditional anti-VEGF compounds: a real-world prospective study","volume":"262","author":"Grimaldi","year":"2024","journal-title":"Graefe\u2019s Arch Clin Exper Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0022","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-023-48190-6","article-title":"Therapeutic effects of faricimab on aflibercept-refractory age-related macular degeneration","volume":"13","author":"Tamiya","year":"2023","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0023","doi-asserted-by":"crossref","first-page":"3569","DOI":"10.1038\/s41433-024-03364-y","article-title":"Real-world six-month outcomes in patients switched to faricimab following partial response to anti-VEGF therapy for neovascular age-related macular degeneration and diabetic macular oedema","volume":"38","author":"Borchert","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0024","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.2147\/OPTH.S424315","article-title":"One-year outcomes of faricimab treatment for aflibercept-resistant neovascular age-related macular degeneration","volume":"17","author":"Rush","year":"2023","journal-title":"Clin Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0025","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s12886-025-03953-9","article-title":"Real-world experience of intravitreal faricimab injection in previously treated neovascular age-related macular degeneration eyes: a case series","volume":"25","author":"Bantounou","year":"2025","journal-title":"BMC Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0026","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.oret.2023.08.018","article-title":"Short-term outcomes of faricimab in patients with neovascular age-related macular degeneration on prior anti-VEGF therapy","volume":"8","author":"Szigiato","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0027","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s00417-023-06222-x","article-title":"Six-month outcomes of switching from aflibercept to faricimab in refractory cases of neovascular age-related macular degeneration","volume":"262","author":"Kataoka","year":"2024","journal-title":"Graefe\u2019s Arch Clin Exper Ophthalmol"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0028","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.oret.2023.10.018","article-title":"Clinical outcomes of faricimab in patients with previously treated neovascular age-related macular degeneration","volume":"8","author":"Pandit","year":"2024","journal-title":"Ophthalmol Retina"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0029","doi-asserted-by":"crossref","first-page":"9087","DOI":"10.1038\/s41598-024-59894-8","article-title":"One-year visual and anatomical outcomes of intravitreal faricimab injection for neovascular age-related macular degeneration after prior brolucizumab treatment","volume":"14","author":"Takahashi","year":"2024","journal-title":"Sci Rep"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0030","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1038\/s41433-024-03218-7","article-title":"Real world efficacy and durability of faricimab in patients with neovascular AMD (nAMD) who had sub-optimal response to prior anti-VEGF therapy","volume":"38","author":"Goodchild","year":"2024","journal-title":"Eye"},{"key":"10.1016\/j.jcjo.2026.02.009_bib0031","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1111\/ceo.14589","article-title":"Outcomes after switching to faricimab in neovascular age-related macular degeneration: data from the Fight Retinal Blindness! Registry","volume":"53","author":"Hunt","year":"2025","journal-title":"Clin Exp Ophthalmol"}],"container-title":["Canadian Journal of Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418226000694?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0008418226000694?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,20]],"date-time":"2026-08-20T00:20:19Z","timestamp":1787185219000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0008418226000694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S0008418226000694"],"URL":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.02.009","relation":{},"ISSN":["0008-4182"],"issn-type":[{"value":"0008-4182","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Faricimab for recalcitrant neovascular age-related macular degeneration: a real-life study following aflibercept nonresponse","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcjo.2026.02.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Canadian Ophthalmological Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}